In cancers of the blood system, MRPL33 affects the receptor tyrosine kinase TrkA or KIT expression levels in acute myeloid leukemia (AML) and neuroblastoma, which has a prognostic value for both types of cancer [31]. This evidence concerns the gene NTRK1 and neuroblastoma.